METHODS FOR REDUCING GRANULOMATOUS INFLAMMATION

• US 20110020325A1
• Filed: 02/27/2009
• Published: 01/27/2011
• Est. Priority Date: 02/29/2008
• Status: Abandoned Application

• Current Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Original Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Inventors: Cheville, John C., Sebo, Thomas J., Inman, Brant A., Kwon, Eugene D.
• Application Number:
  US12/920,021
• Publication Number:
  US 20110020325A1
• Time in Patent Office: Days
• US Class Current: 424/130.1
• CPC Class Codes: A61P 31/06 for tuberculosis
• CPC Class Codes: A61P 31/08 for leprosy
• CPC Class Codes: C07K 16/2827 against B7 molecules, e.g. CD80, CD86
• CPC Class Codes: C12N 15/1138 against receptors or cell surface proteins

Abstract

This document provides methods and materials for reducing bacterial induced granulomatous inflammation in a mammal using agents that reduce B7-H1 expression or activity.

Claims

1. A method for reducing bacterial induced granulomatous inflammation in a mammal, said method comprising administering to said mammal an agent that reduces B7-H1 expression or activity.

2. The method of claim 1, wherein said agent is an antibody.

3. The method of claim 1, wherein said agent is an antisense oligonucleotide.

4. The method of claim 1, wherein said agent is a double-stranded small interfering RNA.

5. The method of claim 1, wherein said mammal is a human.

6. The method of claim 1, wherein the bacterial induced granulomatous inflammation is from a Mycobacterium infection.

7. The method of claim 6, wherein the bacterial induced granulomatous inflammation is from a Mycobacterium tuberculosis, Mycobacterium leprae, or Mycobacterium lepromatosis infection.

8. The method of claim 1, wherein said agent is administered locally to the granulomatous inflammation.

9. The method of claim 1, wherein the bacterial induced granulomatous inflammation is from a Mycobacterium bovis strain bacille Calmette-Gué

rin (BCG) infection.

10. The method of claim 1, further comprising monitoring said patient to determine if granulomatous inflammation is improving with treatment.

11. A method for reducing bacterial induced granulomatous inflammation in a mammal, said method comprising administering to said mammal an agent that reduces B7-H4 expression or activity.

12. The method of claim 11, wherein said agent is an antibody.

13. The method of claim 11, wherein said agent is an antisense oligonucleotide.

14. The method of claim 11, wherein said agent is a double-stranded small interfering RNA.

15. The method of claim 11, wherein said mammal is a human.

16. The method of claim 11, wherein the bacterial induced granulomatous inflammation is from a Mycobacterium infection.

17. The method of claim 16, wherein the bacterial induced granulomatous inflammation is from a Mycobacterium tuberculosis, Mycobacterium leprae, or Mycobacterium lepromatosis infection.

18. The method of claim 11, wherein said agent is administered locally to the granulomatous inflammation.

19. The method of claim 11, wherein the bacterial induced granulomatous inflammation is from a Mycobacterium bovis strain BCG infection.

20. The method of claim 11, further comprising monitoring said patient to determine if granulomatous inflammation is improving with treatment.